Mouse Monoclonal RAB23 Antibody

+ +

•  

   
     All lanes : Anti-RAB23 Antibody at 1:2000 dilution Lane 1: human brain lysate Lane 2: mouse brain lysate Lane 3: MDA-MB-231 whole cell lysate Lane 4: mouse Cerebellum lysate Lane 5: human Cerebellum lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 27 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U-2 OS (human osteosarcoma cell line) cells labeling RAB23 with AM2026a at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-mouse IgG secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on U-2 OS cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin  at 1/100 dilution (red).The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing U-2 OS cells stained with AM2026a(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AM2026a,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Mouse IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(NH174309) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was mouse IgG1(1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

**Background of RAB23 Antibody**

RAB23 is a member of the RAB family of small GTPases, which regulate intracellular vesicle trafficking, membrane fusion, and signal transduction. First identified as a critical player in developmental processes, RAB23 is best known for its role in the Hedgehog (Hh) signaling pathway, where it acts as a negative regulator to modulate cell differentiation and tissue patterning. Mutations in the *RAB23* gene are linked to Carpenter syndrome, a rare autosomal recessive disorder characterized by craniofacial abnormalities, polysyndactyly, and neurodevelopmental defects.

RAB23 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies enable researchers to detect RAB23 protein levels via techniques like Western blotting, immunofluorescence, and immunohistochemistry. Studies using RAB23-specific antibodies have revealed its involvement in diverse processes, including ciliogenesis, autophagy, and cancer progression. For example, dysregulated RAB23 expression has been observed in gliomas, breast cancer, and other malignancies, suggesting its potential as a therapeutic target or biomarker.

Commercial RAB23 antibodies are typically raised against specific epitopes (e.g., human RAB23 N-terminal or C-terminal regions) and validated for species cross-reactivity (human, mouse, rat). Polyclonal and monoclonal variants are available, with applications spanning basic research to clinical sample analysis. Validating antibody specificity using knockout cell lines or siRNA-mediated silencing is critical to avoid off-target artifacts. Overall, RAB23 antibodies continue to advance our understanding of its mechanistic roles in development, disease, and intracellular trafficking networks.